Rheos: applying immune cell reprogramming to autoimmunity
How Rheos is applying immunometabolism to autoimmunity to uncover personalized treatments
As immune cell reprogramming is gaining traction in immuno-oncology, Rheos is applying the concept to autoimmune diseases with a platform that can pinpoint metabolic targets in immune cells to control their phenotype and function.
The company coupled two hot topics on the radar of many pharma companies -- immunometabolism and precision autoimmunity -- and engaged potential partners from the outset to attract its first major deal less than two years after launch.
On Dec. 19, Rheos Medicines